



8TH SKELETAL ENDOCRINOLOGY MEETING

3RD TRANSLATIONAL ESE BONE COURSE

Scientific Preliminary Program

Chairpersons: J.P. Bilezikian, J. Bollerslev, E. Canalis, A. Giustina, B. Obermayer-Pietsch

Friday, 7th April 2017

1.00-2.15pm Satellite Symposium: Osteoporotic fracture current challenges and perspectives

Chair: A. Giustina (I)

The paradox of fracture increase in Italy - P Piscitelli (I)
A new approach to fracture prevention: the Nota 79 algorithm - F. Vescini (I)
Bisphosphonates: the challenge of adherence in real life - S. Giannini (I)
Discussion

2.15-3.30pm Updates on hormones and fractures

Chairs: V. Camozzi (I), A. Giustina (I)

Treatment of adrenal insufficiency and bone - L. De Marinis (I)
Acromegaly and Bone - G. Mazziotti (I)
Teriparatide and fracture: place in guidelines and in the real life - J.P. Bilezikian (US)
Discussion

3.30-4.00pm Opening lecture

Chairs: L. Moro (I), A.J. van der Lelij (NL)
Genetics of osteoporosis - W. Van Hul (NL)

4.00-5.15pm Session I: Advancements in the assessment of fracture risk

Chairs: I. Chiodini (I), S. Minisola (I)
TBS - F.M. Ulivieri (I)
QCT, pQCT & HRpQCT - M. Bouxsein (US)
TC Cone Beam - F. Maffezzoni (I)
Discussion

5.15-6.30pm Session II: Denosumab what's new

Chairs: B. Obermayer-Pietsch (A), L. Sinigaglia (I)
Bone microarchitecture - S. Ferrari (CH)
Combination treatments - S. Polyzos (GR)
Use in cancer-related bone disease - F. Bertoldo (I)
Discussion

6.30-7.00pm ESE Lecture

Chairs: G. Bianchi (I), J. Bollerslev (N)
Long-term management of osteoporosis, when and how to switch - M.C. Zillikens (NL) 30 min

7.00-7.45pm Skeletal hot topics I

Chairs: S. Corbetta (I), P. D'Amelio (I)

Prevalence of malignant neoplasia in patients with primary hyperparathyroidism – E. Cairoli (I)

Exploring epigenetic changes in human parathyroid tumors: long non-coding RNA expression profile reveals heterogeneity among human parathyroid tumors – V. André (I)

The use of denosumab in primary hyperparathyroidism – B. Carloni (I)

Hypovitaminosis D in patients with heart failure: effects on functional capacity and patients' survival – F. Saponaro (I)

Efficacy and safety of PTH (1-34) treatment in hypoparathyroidism: a prospective observational single-centre study – M. Celico (I)

7.45 pm Opening Ceremony and Poster Display

Saturday, 8th April 2017

8.00-8.40am Skeletal hot topics II

Chairs: G. Mazziotti (I), F. Vescini (I)

Tumor-induced osteomalacia mimicking spondyloarthritis: a diagnostic challenge - V. Ravagnani (I)

Micro-RNA signatures in healthy vitamin D deficient men before and after supplementation – V. Francic (A)

Factor affecting fracture risk in adult-onset growth hormone-deficient patients and role of the Growth hormone receptor isoforms – S. Chiloiro (I)

Atypical femoral fractures caused by Glucocorticoid and Bisphosphonate prolonged therapy in premenopausal women: a case report – G. Franceschet (I)

Effects of denosumab on quantitative ultrasound and Dual-Energy X-ray absorptiometry measurements in aromatase inhibitor-treated breast cancer women – F. Bellone (I)

8.40-9.10am Lecture

Chairs: G. Banfi (Mi), E. Canalis (US)

Muscle-bone interaction: The paradigm of Duchenne's Dystrophy - P. Roschger (A)

9.10-10.20am Session III: Hypoparathyroidism

Chairs: J.P. Bilezikian (US), C. Marcocci (I)

Determinants of skeletal phenotype - R. Rizzoli (CH)

Clinical practice guidelines - J. Bollerslev (N)

Replacement therapy - L. Rejnmark (DK)

Discussion

10.20-11.30am Session IV: Rare bone diseases

Chairs: G. Arioli (I), A. Rubinacci (I)

Hypophosphatasia - M.L. Brandi (I)

Osteogenesis imperfecta and Ehlers Danlos Syndrome - A.M. Formenti (I), G. Mazziotti (I)

Hajdu Cheney Syndrome - E. Canalis (US)

Discussion

11.30-12.40pm Session V: Vitamin D and Bone

Chairs: E. Ghigo (I), R. Rizzoli (CH)

Definition, assays and variables in biochemical diagnosis of hypovitaminosis D - M. Plebani (I)

Hypovitaminosis D skeletal phenotype - R. Bouillon (B)

Treatment with Vitamin D - B. Obermayer-Pietsch (A)

Discussion

12.40-1.30pm Session VI: New horizons on anti-osteoporotic therapy

Chairs: A. Angeli (I), S. Gonnelli (I)

Romosozumab – C-C.J. Glüer (Ger)

Abaloparatide - J.P. Bilezikian (US)

Discussion

1.30-1.45pm Conclusive Remarks

